|Bid||77.00 x 100000|
|Ask||77.50 x 100000|
|Day's Range||78.50 - 78.50|
|52 Week Range||58.27 - 79.00|
|Beta (3Y Monthly)||-0.06|
|PE Ratio (TTM)||21.45|
|Forward Dividend & Yield||1.96 (2.52%)|
|1y Target Est||N/A|
On CNBC's "Trading Nation," Mark Newton of Newton Advisors recommended Twitter Inc (NYSE: TWTR ) and Merck & Co., Inc. (NYSE: MRK ) as stocks to buy in the current market environment. He said ...
The U.S. Department of Health and Human Services (HHS) said on Wednesday it will fund the manufacturing of Merck & Co Inc's investigational Ebola vaccine called V920, in response to the outbreak of the deadly virus in the Democratic Republic of the Congo (DRC). The agency said it will give $23 million to Merck to produce the vaccine doses over the next year. HHS has also provided funding for the Department of Defense to transport bulk vaccine materials from Merck's facilities in Germany to its unit in Pennsylvania to produce additional doses of the vaccine.
These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.
Benzinga has examined the prospects for many investor favorite stocks over the past week. Bullish calls included an underappreciated automaker and a leading pharmaceutical. Bearish calls included FAANG ...
George W. Merck reinvented Merck & Co. as a pioneering pharmaceutical powerhouse by putting patient outcomes before immediate profits.
Stocks close slightly lower Tuesday after President Donald Trump renewed his attacks on China, undermining hopes for a trade deal between the world’s two largest economies, while investors digested mixed corporate earnings reports.
U.S. stocks dropped on Tuesday as U.S.-China trade worries pressured technology shares, while the scale of consensus at the Federal Reserve in favor of deeper cuts in interest rates ate into optimism that drove markets to record highs last week. The S&P 500 technology sector fell 0.62%, with Apple Inc's 0.84% drop weighing the most on the index. Wall Street's main indexes have had a slow start to the week, retreating on Monday, and participants are bracing for what message the Fed will send if it pushes ahead with a well-telegraphed move to ease policy that has driven stocks higher since May.
(Bloomberg) -- Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.Merck & Co. beat Wall Street’s sales estimates by almost a billion dollars in the second quarter, and raised its sales and earnings forecast as its blockbuster cancer drug Keytruda is on pace to become a $10-billion-a-year product.The company now predicts 2019 sales of $45.2 billion to $46.2 billion (up from $43.9 billion to $45.1 billion) and adjusted earnings per share of $4.84 to $4.94 (up from $4.67 to $4.79). For more details of the results, click here.Key InsightsCancer blockbuster Keytruda has dominated the market for a new type of oncology treatments that use the immune system to attack tumors. It sold $2.63 billion in the second quarter. While the drug has years of profitable life ahead, its success has also raised questions about Merck’s follow-up act.The answer to that challenge may fall to a new CEO. Merck is preparing for the eventual departure of Chief Executive Officer Kenneth Frazier and research and development leader Roger Perlmutter, who led the company during Keytruda’s development and launch. The company has begun to look internally for a new leader when the two men eventually step down.Keytruda’s success is another blow to Merck’s biggest rival in the field, Bristol-Myers Squibb Co. Last week Bristol-Myers said that its drug, Opdivo, had failed a major trial in lung-cancer patients.Market ReactionThe shares rose 1.8% to $84 at 9:30 a.m. in New York. The stock is up 8% this year so far as of Monday’s close, after outperforming every other stock on the Dow Jones Industrial Average in 2018 with a 36% gain.The company’s profits are up 56% from a year ago. Net income was $2.67 billion in the quarter, compared with $1.71 billion a year prior.(Adds opening share price in XXX paragraph)\--With assistance from Karen Lin.To contact the reporter on this story: Riley Ray Griffin in New York at email@example.comTo contact the editor responsible for this story: Drew Armstrong at firstname.lastname@example.orgFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Pharmaceutical giant Merck & Co. Inc. blew away earnings expectations in the second quarter, thanks to soaring sales of its blockbuster cancer drug Keytruda.
Wall Street's main indexes were set to open lower on Tuesday, as worries about the scale of consensus at the Federal Reserve in favor of deeper cuts in interest rates ate into the positive sentiment that drove markets to record highs last week. Initial price action pointed to losses of 0.4%-0.5% for the Dow Industrials and S&P 500, and a over a half percent fall for the Nasdaq, which included a dip in shares in Apple Inc ahead of its quarterly results later in the day.
Merck shares rose 1.3% to $83.56 in afternoon trading. Sales of Keytruda surged 58% to $2.63 billion in the quarter, ahead of Wall Street estimates for about $2.5 billion. A run of positive clinical data for Keytruda and setbacks for its biggest rival - Bristol-Myers Squibb Co's Opdivo - has led to a dominant position for Merck's drug as an initial treatment for advanced lung cancer, the most lucrative oncology market.
Merck & Co (NYSE: MRK ) reported second-quarter earnings of $1.30 per share, which beat the analyst consensus estimate of $1.16 by 12.07%. This is a 22.64% increase over earnings of $1.06 per share from ...
Merck & Co Inc reported better-than-expected second-quarter results on Tuesday and raised its full-year earnings forecast on strong demand for its blockbuster cancer immunotherapy Keytruda and vaccines. Merck shares rose 1.3% to $83.56 in afternoon trading. Sales of Keytruda surged 58% to $2.63 billion in the quarter, ahead of Wall Street estimates for about $2.5 billion.
Merck & Co. Inc. shares jumped almost 5% in premarket trade Tuesday, after the drug company trounced earnings estimates for the second quarter and raised its guidance. Kenilworth, N.J.-based Merck said it had net income of $2.670 billion, or $1.03 a share, in the quarter, up from $1.707 billion, or 63 cents a share, in the year-earlier quarter. Adjusted per-share earnings came to $1.30, well ahead of the $1.16 FactSet consensus. Sales rose to $11.760 billion from $10.465 billion, also ahead of the FactSet consensus of $10.957 billion. Sales of the company's best-selling drug, the cancer therapy Keytruda, rose to $2.634 billion in the latest quarter from $1.667 billion a year ago, beating the FactSet consensus of $2.521 billion. The company said it was narrowing and raising its full-year guidance and now expects EPS of $3.78 to $3.88, adjusted EPS of $4.84 to $4.94 and revenue of $45.2 billion to $46.2 billion. Shares have gained 7.9% in 2019, while the S&P 500 has gained 20.5% and the Dow Jones Industrial Average has gained 16.7%.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) Acasti Pharma Inc (NASDAQ: ACST ) Array Biopharma Inc ...
Merck & Co (NYSE: MRK ) releases its next round of earnings this Tuesday, July 30. Here's Benzinga's essential guide to Merck's Q2 earnings report. Earnings and Revenue Analysts covering Merck modeled ...
Merck announced Monday the Phase 3 KEYNOTE-522 study that is evaluating its Keytruda in combination with chemotherapy to treat triple-negative breast cancer produced positive results. The late-stage trial met the dual primary endpoints of showing a statistically significant improvement in pathological complete response compared to chemotherapy alone, regardless of PD-L1 status, an interim analysis conducted by the Independent Data Monitoring Committee showed.